|
Franklyn G. Prendergast M.D. Ph.D. Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Professor of Molecular Pharmacology and Experimental Therapeutics Mayo Medical School; Director Mayo Clinic Center for Individualized Medicine; and Director Emeritus Mayo Clinic Cancer Center was elected to the board of directors of Eli Lilly and Company in April 1995.
Born in Linstead Jamaica he received a degree in medicine from the University of the West Indies in 1968. A Rhodes Scholar he received a bachelor of arts degree in physiology from Oxford University in 1971 his doctorate in biochemistry from the University of Minnesota in 1977 and a master's degree in physiology from Oxford University in 1979.
Prendergast began his career at the Mayo Medical School as an instructor in physiology in 1975. In 1977 he became associate consultant in pharmacology at the Mayo Foundation and assistant professor in pharmacology of the Mayo Medical School. Three years later he was named consultant in pharmacology at the Mayo Foundation and associate professor in pharmacology at the Mayo Medical School. In 1985 he became consultant and chair of the department of biochemistry and molecular biology for the Mayo Foundation. He became professor in pharmacology and professor in biochemistry and molecular biology at Mayo Medical School in 1986. He was named director of research for Mayo Rochester in 1992. He serves on the Board of Trustees of the Mayo Foundation and the Mayo Clinic Board of Governors.
Prendergast has been the recipient of numerous honors and awards including Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology (1987) and Mayo Distinguished Investigator (1988). He is a member of the American Chemical Society American Society for Photobiology American Association for the Advancement of Science Biophysical Society Sigma Xi and the American Society for Biochemistry and Molecular Biology and American Cancer Society. | 